Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/168756
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab |
Autor: | Forero-Castro, Maribel; Robledo, Cristina; Lumbreras, Eva CSIC ORCID; Benito, Rocío; Hernandez-Sánchez, Jesus M.; Hernández-Sánchez, María; García, Juan L. CSIC ORCID CVN ; Corchete, Luis A.; Tormo, Mar; Barba, Pere; Menárguez, Javier; Ribera, Jordi; Grande, Carlos; Escoda, Lourdes; Olivier, Carmen; Carrillo Cruz, Estrella; García de Coca, Alfonso; Ribera, Josep-Maria; Hernández, Jesús M. CSIC ORCID | Palabras clave: | Array-based comparative genomic hybridization Next-generation sequencing, outcome Burkitt lymphoma Rituximab |
Fecha de publicación: | 2016 | Editor: | John Wiley & Sons | Citación: | British Journal of Haematology 172(3): 428-438 (2016) | Resumen: | The introduction of Rituximab has improved the outcome and survival rates of Burkitt lymphoma (BL). However, early relapse and refractoriness are current limitations of BL treatment and new biological factors affecting the outcome of these patients have not been explored. This study aimed to identify the presence of genomic changes that could predict the response to new therapies in BL. Forty adolescent and adult BL patients treated with the Dose-Intensive Chemotherapy Including Rituximab (Burkimab) protocol (Spanish Programme for the Study and Treatment of Haematological Malignancies; PETHEMA) were analysed using array-based comparative genomic hybridization (CGH). In addition, the presence of TP53, TCF3 (E2A), ID3 and GNA13 mutations was assessed by next-generation sequencing (NGS). Ninety-seven per cent of the patients harboured genomic imbalances. Losses on 11q, 13q, 15q or 17p were associated with a poor response to Burkimab therapy (P = 0·038), shorter progression-free survival (PFS; P = 0·007) and overall survival (OS; P = 0·009). The integrative analysis of array-CGH and NGS showed that 26·3% (5/19) and 36·8% (7/19) of patients carried alterations in the TP53 and TCF3 genes, respectively. TP53 alterations were associated with shorter PFS (P = 0·011) while TCF3 alterations were associated with shorter OS (P = 0·032). Genetic studies could be used for risk stratification of BL patients treated with the Burkimab protocol. | Descripción: | Part of this study has been reported as an oral presentation at the EHA Meeting in Vienna 2015. | URI: | http://hdl.handle.net/10261/168756 | DOI: | 10.1111/bjh.13849 | Identificadores: | doi: 10.1111/bjh.13849 e-issn: 1365-2141 issn: 0007-1048 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
9
checked on 23-mar-2024
SCOPUSTM
Citations
20
checked on 21-mar-2024
WEB OF SCIENCETM
Citations
18
checked on 27-feb-2024
Page view(s)
290
checked on 28-mar-2024
Download(s)
86
checked on 28-mar-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.